General Information of the Drug (ID: M6APDG04321)
Name
BAP-15
Status
Preclinical
TTD Drug ID
DGP6V3
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Ubiquitin carboxyl-terminal hydrolase 14 (USP14)
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
Response Summary Ubiquitin carboxyl-terminal hydrolase 14 (USP14) is a therapeutic target for BAP-15. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BAP-15 through regulating the expression of Ubiquitin carboxyl-terminal hydrolase 14 (USP14). [1], [2]
References
Ref 1 The m(6)A Reader YTHDF1 Facilitates the Tumorigenesis and Metastasis of Gastric Cancer via USP14 Translation in an m(6)A-Dependent Manner. Front Cell Dev Biol. 2021 Mar 15;9:647702. doi: 10.3389/fcell.2021.647702. eCollection 2021.
Ref 2 Deubiquitinases (DUBs) and DUB inhibitors: a patent review. Expert Opin Ther Pat. 2015;25(10):1191-1208. doi: 10.1517/13543776.2015.1056737. Epub 2015 Jun 16.